Table 4.

Effect of CBD on ERK activation in HEK 293A and STHdh ^Q7/Q7 cells

Agonist	CBD (μM)	EC50 μM (95% CI)a	E max (95% CI)a, b	n (95% CI)a, c	RA ± SEMd
HEK 293A
2‐AG	DMSO	0.12 (0.07–0.22)	1.03 (0.89–1.17)	1.00 (0.97–1.07)	1.00 ± 0.0
	0.01	0.13 (0.08–0.22)	1.05 (0.92–1.18)	0.91 (0.82–1.03)	0.96 ± 0.09
	0.10	0.33 (0.19–0.47)	1.09 (0.90–1.28)	0.63 (0.57–0.72)†	0.40 ± 0.06*
	0.50	0.39 (0.26–0.58)†	0.96 (0.82–1.10)	0.39 (0.29–0.58)†	0.30 ± 0.05*
	1.00	0.57 (0.45–0.72)†	0.83 (0.73–0.93)	0.27 (0.17–0.39)†	0.17 ± 0.05*
	5.00	0.95 (0.81–1.11)†	0.69 (0.61–0.76)†	0.19 (0.11–0.30)†	0.09 ± 0.02*
STHdh Q7/Q7
2‐AG	DMSO	0.50 (0.37–0.68)	0.73 (0.63–0.83)	1.00 (0.91–1.22)	1.00 ± 0.0
	0.01	0.66 (0.44–0.99)	0.70 (0.58–0.83)	0.78 (0.57–0.83)†	0.74 ± 0.2*
	0.10	0.69 (0.48–0.95)	0.67 (0.56–0.77)	0.79 (0.56–0.77)†	0.67 ± 0.1*
	0.50	0.77 (0.52–0.87)	0.57 (0.48–0.65)	0.73 (0.63–0.87)†	0.56 ± 0.1*
	1.00	0.84 (0.69–1.21)†	0.47 (0.37–0.57†	0.70 (0.46–0.81)†	0.44 ± 0.1*
	5.00	1.27 (0.81–1.47)†	0.33 (0.26–0.41)†	0.57 (0.27–0.72)†	0.30 ± 0.1*

CI, confidence interval.

Data shown are means ± SEM or with 95% CI, from six independent experiments.

^aDetermined using nonlinear regression with variable slope (four parameters) analysis.

^bMaximal agonist effect BRET_Eff.

^cHill coefficient.

^dRelative activity, as determined in equation (2).

^† Significantly different from the DMSO vehicle as determined by non‐overlapping CI.

^* P < 0.01, compared with DMSO vehicle; one‐way ANOVA with Dunnett's multiple comparison test.